Beyond the Myths: How Hormone Therapy Is Re-Emerging in Women's Midlife Healthcare
For over two decades, a single study shaped and arguably derailed the way millions of women experienced menopause. When the Women's Health Initiative (WHI) trial was halted in July 2002, its headline finding that combined hormone therapy raised the risk of breast cancer and cardiovascular events ricocheted through clinics, newsrooms, and women's conversations around the world. Prescriptions dropped sharply. Women already on hormone therapy stopped it. Doctors became cautious to the point of reluctance. A generation of women was left to manage a significant biological transition with little clinical support and a great deal of fear.
What did not travel nearly as far was the correction. Long-term reanalyses of the same WHI data painted a substantially different picture. The original trial had enrolled women with an average age of 63, many of them over 10 years post-menopausal and already carrying established cardiovascular risk. A 2024 review in Gynecological and Reproductive Endocrinology and Metabolism, re-examining 21 years of WHI data, found that when the widely cited increased breast cancer risk is converted to absolute terms, it amounts to just 0.08% per year, or 0.40% over 5 years of combined MHT use. As Drs. Taylor and Davis SR wrote in a 2025 Lancet Diabetes and Endocrinology commentary, it is time to revisit the recommendations for initiation of menopausal hormone therapy entirely, reflecting the weight of evidence that has accumulated since 2002.
What the Revised Evidence on Hormone Therapy Actually Shows
The rehabilitation of hormone therapy is not a matter of opinion. It is a matter of accumulating, high-quality clinical evidence across multiple independent research bodies.
The clearest expression of this shift is what researchers now call the "timing hypothesis" or "critical window." The ELITE trial (Early versus Late Intervention Trial with Estradiol), which directly compared early initiation (within 6 years of menopause) versus late initiation (10 or more years after menopause), found that menopausal hormone therapy (MHT) significantly reduced carotid intima-media (artery wall) thickness in women who initiated early, while no such benefit was observed in those who initiated late.The Danish Osteoporosis Prevention Study reinforced this: approximately 1,000 younger postmenopausal women who received MHT for 10 years experienced a 52% reduction in a composite outcome of death, heart failure, and myocardial infarction. Dr. Lisa Mosconi, neuroscientist and Director of the Women's Brain Initiative at Weill Cornell Medicine, reached the same conclusion from a different direction: her meta-analysis of 51 studies found consistent support that MHT initiated near menopause protects brain health, while initiation beyond the critical window may offer no benefit and potentially increase dementia risk.
On sleep, a 2024 Korean study reported mean Pittsburgh Sleep Quality Index scores improving from 7.8 to 6.1 after 1 and 3 months of MHT. On bone health, the 2024-2025 ASRM and ESHRE guidelines confirm that physiological doses of transdermal estradiol combined with micronised progesterone reduce fracture risk by 30-50%. On cardiovascular health, longitudinal WHI data spanning 13 years of follow-up revealed no significant differences in stroke risk between MHT and placebo groups irrespective of age, and meta-analyses suggest MHT does not increase stroke risk in postmenopausal women with established cardiovascular disease.
On breast cancer, the picture is more nuanced than fear has allowed, and formulation matters enormously. A Collaborative Group meta-analysis of 108,647 postmenopausal women found that 5 years of combined estrogen-progestin MHT increases breast cancer incidence by 1 in every 200 users. Estrogen-only MHT tells a different story: the long-term WHI follow-up found it was associated with a 23% reduction in breast cancer diagnosis and a 40% reduction in breast cancer death. At an FDA Expert Panel on Menopausal and Hormone Replacement Therapy convened in July 2025, investigators publicly acknowledged the need to contextualise findings that had been misinterpreted in public discourse for over two decades.
Science has moved. Public perception and clinical practice across much of the world are catching up slowly.
The India-Specific Problem
In India, the gap between evidence and access is not merely a matter of catching up with global research. It is a structural, cultural, and systemic barrier that plays out at scale.
A 2025 study published in Climacteric, surveying over 32,500 women from underprivileged communities across India, found that 50% were unaware of the effects of menopause entirely, and 62% were unaware of available treatments. Critically, when a healthcare provider explained and offered treatment, 48% said they were willing to take it. The problem is not resistance. It is access to accurate information.
A 2025 scoping review on menopause in low and middle-income countries found that MHT use in Asia ranged from just 0.6% to 23%, with limited awareness, lack of physician recommendation, and fear of side effects cited as the most common barriers. In India, non-hormonal approaches, including herbal remedies, dietary modifications, and stress-reduction techniques, remain the default, not because they are more effective, but because they are more culturally familiar and more readily available.
The consequences are not abstract. Indian women reach menopause nearly five years earlier than the global average. They spend more years in the post-menopausal state and carry higher baseline risks for osteoporosis, cardiovascular disease, and type 2 diabetes, conditions whose risks may be reduced or better managed with appropriate, timely menopausal hormone therapy in suitable women. A 2025 BMJ article described menopause as a "midlife crisis for women in India," highlighting rural women's experience of limited healthcare access, low awareness, and higher rates of premature menopause as compounding factors in an already underserved transition.
The fear around MHT that took root globally in 2002 hit Indian women doubly hard, because it arrived before a culture of open menopause conversation had even begun. The correction, along with decades of revised evidence, updated guidelines, and a nuanced understanding of timing, formulation, and route, has reached far fewer women than the original fear did.
What Re-Emergence Actually Looks Like
Globally, the clinical conversation around hormone therapy has shifted from avoidance to individualization. The 2025 Korean Society of Menopause Guidelines, the 2024 International Menopause Society White Paper, the 2024 NICE guidance, and the 2024-2025 ASRM and ESHRE frameworks all converge on the same position: MHT is the most effective treatment for vasomotor symptoms and genitourinary syndrome of menopause, offers meaningful protection against bone loss and cardiovascular disease when initiated early; it carries a benefit-risk profile that, for most women under 60 initiating within 10 years of menopause, is firmly in favor of treatment.
The formulation matters. Body-identical estradiol is now preferred over conjugated equine estrogens. Micronized progesterone carries a more favorable breast cancer risk profile than synthetic progestins. Transdermal delivery avoids first-pass hepatic metabolism and significantly reduces VTE and stroke risk compared to oral estrogen. These are not minor distinctions. They are the difference between the therapy studied in the 2002 WHI trial and the therapy being recommended today.
As Lancet Obstetrics, Gynaecology and Women's Health (2025) noted, almost all momentum in longitudinal menopause investigation occurred in the 1990s, and the field is urgently overdue for research that includes diverse, non-Caucasian populations, alongside updated clinical guidance. Re-emergence means gynecologists are trained for this conversation, women arriving at consultations are informed, and platforms are built to close the gap between what evidence supports and what women are actually told.
Where Miyara Fits In
The gap between evidence and access does not close on its own. It closes when women have accurate, current, and culturally relevant information, as well as the tools to act on it.
Miyara was built precisely for this moment. The platform combines proven clinical therapies, smart technology, and real expert support to help women manage hormonal health with confidence. The Miyara app allows women to track over 20 symptoms with clinical-grade precision, generating a personalized Miyara Score that maps where they are in their hormonal transition. Mia, Miyara's AI health companion, draws on a curated, research-backed database to answer questions about symptoms, treatment options, and hormone therapy whenever they arise. The platform's health assessment analyzes over 40 parameters to generate personalized insights, the kind of personalised baseline that helps women arrive at their gynaecologist's appointment with better questions and clearer answers.
Miyara's self-paced CBT for Hot Flashes program has been described by members as genuinely life-changing, evidence that symptom management does not have to wait for a prescription. When clinical guidance is needed, the platform's network of menopause-trained specialists is available for direct consultation in a country where finding such a specialist has historically meant knowing the right person or living in the right city.
The communities built around Miyara, where women across India share experiences, ask questions, and normalize a conversation their mothers never had, are part of the infrastructure of change. The fear that kept women away from hormone therapy for two decades was partly a product of silence. Breaking that silence is not incidental to Miyara. It IS the point.
The science of hormone therapy has been rehabilitated. The task now is to ensure that rehabilitation reaches the women who need it, and in India, that work is only beginning to gain momentum.
Get support for Perimenopause and Menopause
Comments